Forte Biosciences, Inc.

FBRX

$76.99

Updated: 22/09/2026, 10:27:57

Market Cap

$1.58B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for FBRX

Company Profile

Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.

USD

NASDAQ

CEO: Paul A. Wagner

Employees: 23

https://www.fortebiorx.com

Asset Summaries

Latest generated summaries for FBRX

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for FBRX.

Share price: $76.99
Market cap: $1.58B
Exchange: NASDAQ
Currency: USD
CEO: Paul A. Wagner
Employees: 23
IPO date: 13/04/2017
Beta: 2.645
Last dividend: $0.00
Day range: $76.97 – $76.99
52-week range: $10.11 – $77.20
1-day performance: 0.00%
1-year performance: 661.52%
Current drawdown (1Y): -0.27%
CIK: 0001419041
CUSIP: 34962G208
ISIN: US34962G2084
Created: 07/12/2025, 03:54:54
Last update: 22/09/2026, 10:27:57

Track Forte Biosciences, Inc. with an AI analyst

See which prediction-market events move FBRX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to FBRX from your Railway `news_articles` table.

Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts

Seeking Alpha • STOCK • 10/04/2026, 16:15:40

Forte Biosciences Announces Pricing of $150 Million Public Offering

Business Wire • STOCK • 08/04/2026, 23:30:00

Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research • STOCK • 25/02/2026, 14:01:23